UNSPSC 51372701: Meptazinol

This classification denotes an opioid receptor agonist with the molecular formula C15H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 18Y7S5JKZD, chemically known as phenol, 3-(3-ethylhexahydro-1-methyl-1h-azepin-3-yl)- but generally known as meptazinol, which bears US NIH Compound Identifier 41049. European Medicines Agency schedules Meptazinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08761MIG.

UNSPSC 51372701 Meptazinol is a Commodity code that nominally describes a single pharmaceutical product, but the recent state and local opportunities tagged under it diverge significantly from this narrow scope. The actual procurements involve broader pharmaceutical and health-system supplies: naloxone and drug deactivation systems for community health departments, direct-to-manufacturer prescription program infrastructure, and generic multi-source pharmaceuticals distributed through authorized wholesalers to state and local facilities. State and local buyers under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida issued an IFB for naloxone and drug deactivation systems; the Texas Health and Human Services Commission posted an RFI exploring direct-to-manufacturer prescription models; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic pharmaceuticals and OTC products.

The code shows activity concentrated in the South and Upper Midwest, with the most recent and detailed opportunity in Florida (Seminole County's IFB60459723LAS, due July 26, 2023, for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries), Texas (the HHS RFI HHS0017013 posted April 3, 2026, to gather vendor capabilities for direct contracting models), and Minnesota (MMCAP's S1070000015802 RFP, due March 26, 2026, covering generic pharmaceuticals across multiple states including Oregon). The MMCAP procurement is the most structured, requiring NDC-level product specifications, cGMP and DSCSA compliance, relationships with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), commercial general liability of at least $5 million per occurrence, and price evaluation weighted 75 percent on competitiveness. The code shows limited recent activity overall, and the mismatch between the narrow Meptazinol scope and the heterogeneous products actually being solicited suggests the code's taxonomic alignment with state and local opportunities is inconsistent.